Validation of 24-hour flucytosine MIC determination by comparison with 48-hour determination by the clinical and laboratory standards institute M27-A3 broth microdilution reference method

Journal of Clinical Microbiology

Volumn 49, Issue 12, 2011, Pages 4322-4325

  Lockhart, Shawn R ^a   Bolden, Carol B ^a   Iqbal, Naureen ^a   Kuykendall, Randall J ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUCYTOSINE;

ARTICLE; BROTH DILUTION; CANDIDA; CANDIDA ALBICANS; CANDIDA BRACARENSIS; CANDIDA CATENULATA; CANDIDA DUBLINIENSIS; CANDIDA FAMATA; CANDIDA FERMENTATI; CANDIDA GLABRATA; CANDIDA KRUSEI; CANDIDA METAPSILOSIS; CANDIDA NIVARIENSIS; CANDIDA NORVEGENSIS; CANDIDA ORTHOPSILOSIS; CANDIDA PARAPSILOSIS; CANDIDA PARARUGOSA; CANDIDA RUGOSA; CANDIDA TROPICALIS; CLAVISPORA LUSITANIAE; CONTROLLED STUDY; INTERMETHOD COMPARISON; KLUYVEROMYCES MARXIANUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PICHIA ANOMALA; PICHIA GUILLIERMONDII; PRIORITY JOURNAL; VALIDATION PROCESS;

ANTIFUNGAL AGENTS; CANDIDA; FLUCYTOSINE; HUMANS; ITRACONAZOLE; MICROBIAL SENSITIVITY TESTS; TIME FACTORS;

EID: 82455220441     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.05479-11     Document Type: Article

References (31)

1. Arnold, H. M., et al. 2010. Hospital resource utilization and costs of inappropriate treatment of candidemia. Pharmacotherapy 30:361-368.
2. Baddley, J. W., et al. 2004. Utility of real-time antifungal susceptibility testing for fluconazole in the treatment of candidemia. Diagn. Microbiol. Infect. Dis. 50:119-124. (Pubitemid 39335847)
3. Clinical and Laboratory Standards Institute. 2008. M27-A3 reference method for broth dilution antifungal susceptibility testing of yeasts: approved standard, 3rd ed. Clinical and Laboratory Standards Institute, Wayne, Pa.
4. Clinical and Laboratory Standards Institute. 2008. M27-S3 reference method for broth dilution antifungal susceptibility testing of yeasts: 3rd informational supplement. Clinical and Laboratory Standards Institute, Wayne, Pa.
5. Collins, C. D., G. A. Eschenauer, S. L. Salo, and D. W. Newton. 2007. To test or not to test: a cost minimization analysis of susceptibility testing for patients with documented Candida glabrata fungemias. J. Clin. Microbiol. 45:1884-1888. (Pubitemid 46933921)
6. Espinel-Ingroff, A., et al. 2005. Comparison of visual 24-hour and spectrophotometric 48-hour MICs to CLSI reference microdilution MICs of fluconazole, itraconazole, posaconazole, and voriconazole for Candida spp.: a collaborative study. J. Clin. Microbiol. 43:4535-4540. (Pubitemid 41298239)
7. Espinel-Ingroff, A., E. Canton, J. Peman, M. G. Rinaldi, and A. W. Fothergill. 2009. Comparison of 24-hour and 48-hour voriconazole MICs as determined by the Clinical and Laboratory Standards Institute broth microdilution method (M27-A3 document) in three laboratories: results obtained with 2,162 clinical isolates of Candida spp. and other yeasts. J. Clin. Microbiol. 47:2766-2771.
8. Espinel-Ingroff, A., et al. 2004. Multicenter comparison of the Sensititre YeastOne colorimetric antifungal panel with the NCCLS M27-A2 reference method for testing new antifungal agents against clinical isolates of Candida spp. J. Clin. Microbiol. 42:718-721. (Pubitemid 38222652)
9. Espinel-Ingroff, A., et al. 1999. Multicenter comparison of the sensititre YeastOne colorimetric antifungal panel with the National Committee for Clinical Laboratory standards M27-A reference method for testing clinical isolates of common and emerging Candida spp., Cryptococcus spp., and other yeasts and yeast-like organisms. J. Clin. Microbiol. 37:591-595. (Pubitemid 29091269)
10. Garey, K. W., et al. 2006. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin. Infect. Dis. 43:25-31. (Pubitemid 43939072)
11. Hadley, S., J. A. Martinez, L. McDermott, B. Rapino, and D. R. Snydman. 2002. Real-time antifungal susceptibility screening aids management of invasive yeast infections in immunocompromised patients. J. Antimicrob. Chemother. 49:415-419. (Pubitemid 34162641)
12. Hassan, I., G. Powell, M. Sidhu, W. M. Hart, and D. W. Denning. 2009. Excess mortality, length of stay and cost attributable to candidaemia. J. Infect. 59:360-365.
13. Hospenthal, D. R., C. K. Murray, and M. G. Rinaldi. 2004. The role of antifungal susceptibility testing in the therapy of candidiasis. Diagn. Microbio. l Infect. Dis. 48:153-160. (Pubitemid 38340513)
14. Martin, G. S., D. M. Mannino, S. Eaton, and M. Moss. 2003. The epidemiology of sepsis in the United States from 1979 through 2000. N. Engl. J. Med. 348:1546-1554. (Pubitemid 36437931)
15. Morrell, M., V. J. Fraser, and M. H. Kollef. 2005. Delaying the empiric treatment of Candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob. Agents Chemother. 49:3640-3645. (Pubitemid 41233011)
16. Morgan, J., et al. 2005. Excess mortality, hospital stay, and cost due to candidemia: a case-control study using data from population-based candidemia surveillance. Infect. Control Hosp. Epidemiol. 26:540-547. (Pubitemid 40896144)
17. National Committee for Clinical Laboratory Standards. 1997. Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard. NCCLS document M27-A. National Committee for Clinical Laboratory Standards, Wayne, Pa.
18. Ostrosky-Zeichner, L., et al. 2008. Rationale for reading fluconazole MICs at 24 hours rather than 48 hours when testing Candida spp. by the CLSI M27-A2 standard method. Antimicrob. Agents Chemother. 52:4175-4177.
19. Pappas, P. G., et al. 2009. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin. Infect. Dis. 48:503-535.
20. Parkins, M. D., D. M. Sabuda, S. Elsayed, and K. B. Laupland. 2007. Adequacy of empirical antifungal therapy and effect on outcome among patients with invasive Candida species infections. J. Antimicrob. Chemother. 60:613-618. (Pubitemid 47299877)
21. Perfect, J. R., et al. 2010. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America. Clin. Infect. Dis. 50:291-322.
22. Pfaller, M. A., et al. 2011. Clinical breakpoints for voriconazole and Candida spp. revisited: review of microbiologic, molecular, pharmacodynamic, and clinical data as they pertain to the development of species-specific interpretive criteria. Diagn. Microbiol. Infect. Dis. 70:330-343.
23. Pfaller, M. A., et al. 2010. Wild-type MIC distributions, epidemiological cutoff values and species-specific clinical breakpoints for fluconazole and Candida: time for harmonization of CLSI and EUCAST broth microdilution methods. Drug Resist. Updat. 13:180-195.
24. Pfaller, M. A., et al. 2008. Validation of 24-hour fluconazole MIC readings versus the CLSI 48-hour broth microdilution reference method: results from a global Candida antifungal surveillance program. J. Clin. Microbiol. 46:3585-3590.
25. Pfaller, M. A., et al. 2011. Validation of 24-hour posaconazole and voriconazole MIC readings versus the CLSI 48-hour broth microdilution reference method: application of epidemiological cutoff values to results from a global Candida antifungal surveillance program. J. Clin. Microbiol. 49:1274-1279.
26. Pfaller, M. A., et al. 2002. In vitro activities of 5-fluorocytosine against 8,803 clinical isolates of Candida spp.: global assessment of primary resistance using National Committee for Clinical Laboratory Standards susceptibility testing methods. Antimicrob. Agents Chemother. 46:3518-3521. (Pubitemid 35192920)
27. Pfaller, M. A., et al. 1998. Multisite reproducibility of MIC results by the Sensititre YeastOne colorimetric antifungal susceptibility panel. Diagn. Microbiol. Infect. Dis. 31:543-547. (Pubitemid 28414495)
28. Vermes, A., H. J. Guchelaar, and J. Dankert. 2000. Flucytosine: a review of its pharmacology, clinical indications, pharmacokinetics, toxicity and drug interactions. J. Antimicrob. Chemother. 46:171-179. (Pubitemid 30639285)
29. Waldorf, A. R., and A. Polak. 1983. Mechanisms of action of 5-fluorocytosine. Antimicrob. Agents Chemother. 23:79-85. (Pubitemid 13168413)
30. Wisplinghoff, H., et al. 2004. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin. Infect. Dis. 39:309-317. (Pubitemid 39050477)
31. Zilberberg, M. D., et al. 2010. Inappropriate empiric antifungal therapy for candidemia in the ICU and hospital resource utilization: a retrospective cohort study. BMC Infect. Dis. 10:150.